Organon & Co. (OGN)

$18.55

+0.02

(+0.11%)

Market is closed - opens 8 PM, 23 Feb 2024

Insights on Organon & Co.

  • Decreasing Revenue

    Revenue is down for the last 2 quarters, 1.60B → 1.51B (in $), with an average decrease of 5.5% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 2 quarters, 242.0M → 58.0M (in $), with an average decrease of 76.0% per quarter

  • Vs LLY

    In the last 1 year, Eli Lilly And Company has given 126.7% return, outperforming this stock by 157.6%

Performance

  • $18.28
    $18.64
    $18.55
    downward going graph

    1.46%

    Downside

    Day's Volatility :1.93%

    Upside

    0.48%

    downward going graph
  • $10.84
    $25.71
    $18.55
    downward going graph

    41.56%

    Downside

    52 Weeks Volatility :57.84%

    Upside

    27.85%

    downward going graph

Returns

PeriodOrganon & Co.Sector (Health Care)Index (Russel 2000)
3 Months
64.86%
11.5%
0.0%
6 Months
-16.38%
9.2%
0.0%
1 Year
-30.94%
12.0%
-6.6%
3 Years
-48.53%
27.4%
-21.4%

Highlights

Market Capitalization
4.7B
Book Value
- $2.3
Dividend Share
1.12
Dividend Yield
6.06%
Earnings Per Share (EPS)
3.99
PE Ratio
4.63
Wall Street Target Price
21.25
Profit Margin
16.33%
Operating Margin TTM
23.84%
Return On Assets TTM
7.61%
Return On Equity TTM
0.0%
Revenue TTM
6.3B
Revenue Per Share TTM
24.54
Quarterly Revenue Growth YOY
7.6%
Gross Profit TTM
3.9B
EBITDA
1.8B
Diluted Eps TTM
3.99
Quarterly Earnings Growth YOY
4.07
EPS Estimate Current Year
4.27
EPS Estimate Next Year
4.47
EPS Estimate Current Quarter
1.07
EPS Estimate Next Quarter
1.0

Analyst Recommendation

Buy
    61%Buy
    30%Hold
    7%Sell
Based on 13 Wall street analysts offering stock ratings for Organon & Co.(by analysts ranked 0 to 5 stars)
Based on 13 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
8
8
7
Hold
4
4
5
Sell
1
1
1

Analyst Forecast

What analysts predicted

Upside of 14.56%

Current $18.55
Target $21.25

Company Financials

FY18Y/Y Change
Revenue
9.8B
↓ 6.89%
Net Income
2.2B
↑ 19.54%
Net Profit Margin
22.02%
↑ 4.87%
FY19Y/Y Change
Revenue
7.8B
↓ 20.46%
Net Income
3.2B
↑ 49.47%
Net Profit Margin
41.38%
↑ 19.36%
FY20Y/Y Change
Revenue
8.1B
↑ 4.1%
Net Income
2.2B
↓ 32.88%
Net Profit Margin
26.68%
↓ 14.7%
FY21Y/Y Change
Revenue
6.3B
↓ 22.13%
Net Income
1.4B
↓ 37.45%
Net Profit Margin
21.43%
↓ 5.25%
FY22Y/Y Change
Revenue
6.2B
↓ 2.06%
Net Income
917.0M
↓ 32.12%
Net Profit Margin
14.85%
↓ 6.58%
FY23Y/Y Change
Revenue
6.2B
↓ 0.39%
Net Income
585.0M
↓ 36.21%
Net Profit Margin
9.51%
↓ 5.34%
Q2 FY22Q/Q Change
Revenue
1.6B
↑ 1.15%
Net Income
234.0M
↓ 32.76%
Net Profit Margin
14.76%
↓ 7.45%
Q3 FY22Q/Q Change
Revenue
1.5B
↓ 3.03%
Net Income
227.0M
↓ 2.99%
Net Profit Margin
14.77%
↑ 0.01%
Q4 FY22Q/Q Change
Revenue
1.5B
↓ 3.38%
Net Income
108.0M
↓ 52.42%
Net Profit Margin
7.27%
↓ 7.5%
Q1 FY23Q/Q Change
Revenue
1.5B
↑ 3.57%
Net Income
177.0M
↑ 63.89%
Net Profit Margin
11.51%
↑ 4.24%
Q2 FY23Q/Q Change
Revenue
1.6B
↑ 4.55%
Net Income
242.0M
↑ 36.72%
Net Profit Margin
15.05%
↑ 3.54%
Q3 FY23Q/Q Change
Revenue
1.5B
↓ 5.53%
Net Income
58.0M
↓ 76.03%
Net Profit Margin
3.82%
↓ 11.23%
FY18Y/Y Change
Total Assets
10.5B
-
Total Liabilities
4.1B
-
FY19Y/Y Change
Total Assets
10.5B
↑ 0.51%
Total Liabilities
3.5B
↓ 15.27%
FY20Y/Y Change
Total Assets
10.4B
↓ 1.08%
Total Liabilities
11.3B
↑ 220.35%
FY21Y/Y Change
Total Assets
10.7B
↑ 2.37%
Total Liabilities
12.2B
↑ 8.31%
FY22Y/Y Change
Total Assets
11.0B
↑ 2.57%
Total Liabilities
11.8B
↓ 2.81%
Q2 FY22Q/Q Change
Total Assets
10.6B
↑ 0.16%
Total Liabilities
11.8B
↓ 0.81%
Q3 FY22Q/Q Change
Total Assets
10.4B
↓ 1.67%
Total Liabilities
11.5B
↓ 2.11%
Q4 FY22Q/Q Change
Total Assets
11.0B
↑ 4.96%
Total Liabilities
11.8B
↑ 2.99%
Q1 FY23Q/Q Change
Total Assets
10.8B
↓ 1.75%
Total Liabilities
11.5B
↓ 2.93%
Q2 FY23Q/Q Change
Total Assets
11.0B
↑ 2.01%
Total Liabilities
11.5B
↑ 0.3%
Q3 FY23Q/Q Change
Total Assets
11.0B
↑ 0.3%
Total Liabilities
11.6B
↑ 0.58%
FY18Y/Y Change
Operating Cash Flow
3.7B
↑ 7.84%
Investing Cash Flow
-69.0M
↑ 23.21%
Financing Cash Flow
-4.2B
↑ 23.49%
FY19Y/Y Change
Operating Cash Flow
2.8B
↓ 24.95%
Investing Cash Flow
-102.0M
↑ 47.83%
Financing Cash Flow
-2.6B
↓ 37.06%
FY20Y/Y Change
Operating Cash Flow
2.2B
↓ 20.96%
Investing Cash Flow
-258.0M
↑ 152.94%
Financing Cash Flow
-2.2B
↓ 17.02%
FY21Y/Y Change
Operating Cash Flow
2.5B
↑ 12.39%
Investing Cash Flow
-481.0M
↑ 86.43%
Financing Cash Flow
-1.3B
↓ 38.71%
FY22Y/Y Change
Operating Cash Flow
858.0M
↓ 65.09%
Investing Cash Flow
-420.0M
↓ 12.68%
Financing Cash Flow
-433.0M
↓ 67.52%
Q2 FY22Q/Q Change
Operating Cash Flow
151.0M
↑ 22.76%
Investing Cash Flow
-83.0M
↑ 31.75%
Financing Cash Flow
-183.0M
↑ 101.1%
Q3 FY22Q/Q Change
Operating Cash Flow
317.0M
↑ 109.93%
Investing Cash Flow
-213.0M
↑ 156.63%
Financing Cash Flow
-77.0M
↓ 57.92%
Q4 FY22Q/Q Change
Operating Cash Flow
267.0M
↓ 15.77%
Investing Cash Flow
-420.0M
↑ 97.18%
Financing Cash Flow
-82.0M
↑ 6.49%
Q1 FY23Q/Q Change
Operating Cash Flow
114.0M
↓ 57.3%
Investing Cash Flow
-54.0M
↓ 87.14%
Financing Cash Flow
-326.0M
↑ 297.56%
Q2 FY23Q/Q Change
Operating Cash Flow
27.0M
↓ 76.32%
Investing Cash Flow
-70.0M
↑ 29.63%
Financing Cash Flow
-88.0M
↓ 73.01%
Q3 FY23Q/Q Change
Operating Cash Flow
261.0M
↑ 866.67%
Investing Cash Flow
-179.0M
↑ 155.71%
Financing Cash Flow
-78.0M
↓ 11.36%

Technicals Summary

Sell

Neutral

Buy

Organon & Co. is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Organon & Co.
Organon & Co.
18.1%
-16.38%
-30.94%
-48.53%
-48.53%
Eli Lilly And Company
Eli Lilly And Company
18.23%
34.72%
126.67%
271.69%
501.54%
Johnson & Johnson
Johnson & Johnson
-2.33%
-4.42%
0.57%
-1.97%
16.16%
Merck & Co. Inc.
Merck & Co. Inc.
7.28%
19.48%
17.37%
70.99%
58.62%
Abbvie Inc
Abbvie Inc
5.9%
18.15%
16.24%
63.59%
118.87%
Pfizer Inc.
Pfizer Inc.
-2.26%
-24.89%
-34.71%
-19.24%
-35.59%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Organon & Co.
Organon & Co.
4.63
4.63
NA
4.27
0.0
0.08
0.06
-2.3
Eli Lilly And Company
Eli Lilly And Company
136.89
136.89
1.81
12.52
0.47
0.12
0.01
12.48
Johnson & Johnson
Johnson & Johnson
30.42
30.42
5.76
10.66
0.18
0.08
0.03
28.57
Merck & Co. Inc.
Merck & Co. Inc.
909.79
909.79
0.88
8.57
0.01
0.05
0.02
16.27
Abbvie Inc
Abbvie Inc
64.51
64.51
1.64
10.39
0.33
0.09
0.04
6.85
Pfizer Inc.
Pfizer Inc.
74.65
74.65
1.17
2.2
0.02
0.05
0.06
17.17
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Organon & Co.
Organon & Co.
Buy
$4.7B
-48.53%
4.63
16.33%
Eli Lilly And Company
Eli Lilly And Company
Buy
$717.4B
501.54%
136.89
15.36%
Johnson & Johnson
Johnson & Johnson
Hold
$380.2B
16.16%
30.42
41.28%
Merck & Co. Inc.
Merck & Co. Inc.
Buy
$322.8B
58.62%
909.79
0.61%
Abbvie Inc
Abbvie Inc
Buy
$309.8B
118.87%
64.51
8.95%
Pfizer Inc.
Pfizer Inc.
Buy
$156.0B
-35.59%
74.65
3.62%

Institutional Holdings

  • Vanguard Group Inc

    12.30%
  • BlackRock Inc

    6.15%
  • State Street Corporation

    5.37%
  • Amvescap Plc.

    4.01%
  • Massachusetts Financial Services Company

    3.99%
  • Geode Capital Management, LLC

    2.24%

Corporate Announcements

  • Organon & Co. Dividends March,2024

    In the quarter ending March,2024. Organon & Co. has declared dividend of $0.28

    Read More

Company Information

organon is a dutch pharmaceutical company started in oss the netherlands. it is famous for "the pil" a birthcontrol pil. organon grew as a company and was taken over by schering plough and later on by merck and continues as msd in the netherlands. in the old days the compant was great, it used to be "gezellig" !

Organization
Organon & Co.
Employees
10000
CEO
Mr. Kevin Ali
Industry
Healthcare

FAQs